Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
about
Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cellsAntiangiogenic Steroids in Human Cancer Therapy.Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesCritical appraisal of bevacizumab in the treatment of ovarian cancerOvarian cancer standard of care: are there real alternatives?Precision targeted therapy of ovarian cancerPlasma levels of soluble CD105 correlate with metastasis in patients with breast cancerVSGP/F-spondin: a new ovarian cancer marker.TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patientsAntiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in miceVEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial NeoplasmsBridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites.Prognostic biomarkers in ovarian cancer.Vascular endothelial growth factor in ovarian cancer.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.Inhibition of vascular endothelial growth factor in the treatment of solid tumors.Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.Angiogenic tumor markers, antiangiogenic agents and radiation therapy.Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts.Novel biomarker candidates for the diagnosis of ovarian clear cell carcinomaOpen-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study groupDoes VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Ovarian cancer biomarkers: current options and future promise.Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancerEffect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.Role of VEGF and CD44v6 in differentiating benign from malignant ascites.High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma.Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer.Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival.Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts.Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
P2860
Q24685207-30E26979-C76B-4BF4-A92C-EB66DE7B425DQ24795360-BDF416C3-1DAE-41A1-84AE-A6F70EF3AAB2Q26738643-E467C0AA-975C-432C-AE1E-82609F44CBEBQ26751280-DD1E4508-8125-4F14-8618-D52CDAC20A0AQ26830403-EDD35A8B-2807-4C28-9F13-67274F38FB88Q26862249-8CC5165B-925C-48A4-BF89-B3FD450DE21BQ28078658-066D29B5-67C2-4F22-968B-E8F4A47848FEQ28141264-021261D4-0993-4C05-BA3A-BF2F8168CC7EQ33221792-11191324-8E19-426D-980D-2C3C8B58DFB0Q33553922-D008417F-8AF2-4421-A252-EE98CC2411DDQ33713224-3C250C09-C496-4537-862F-AD76D813CB7DQ33741593-002B3A7A-1DFD-4D02-AC67-9EF577C89200Q33780689-3CC44CB8-44EC-4256-AC8D-E2087DBBCD2FQ33800676-F45E637A-C9AF-4753-B094-28437CD86322Q33946367-20292815-8C39-49ED-862C-6E90F6583543Q34086636-8CBF0A23-819F-40B0-A4F0-D4F2C3E1FAD4Q34107669-5D822141-71AF-421A-99BF-31C134D27F5AQ34139923-5B5C9BB4-B83A-44CF-871F-0DA26EE3DE66Q34378095-1A9351DB-74E3-425C-A97D-0E479604E3F2Q34457421-42F9DEEF-2B28-4AEC-8484-DF14B297371EQ34514125-438A9ACB-9C5A-40E4-80DE-0DB9B49AB126Q34974876-975EF069-62C7-4919-A84F-0D5A67B3DF97Q35160210-E2CCE2B4-F9B8-4E2B-BC2E-C11542435079Q35747351-F2F213BC-665B-46F2-8172-97FC053ABD95Q35871283-5E0E42B7-5096-4955-BACC-4A3626B516E9Q35879884-C8C581E0-96A8-4592-8618-698B85871A26Q35921404-2BB96835-8BE4-480F-A619-6C70BFF93C97Q35941074-E0E2CCF4-6979-4D15-9693-A92569BB3832Q35954103-47A011E3-4A7A-4691-9D17-9BB40BB86DCCQ36054395-AD738525-19FB-47D5-99F8-9A935CF2CC4CQ36077140-BAAB4B86-DD9F-4CA2-B150-F5557A6F95EEQ36099292-02421ECE-4A2D-44A7-B983-E1A664F923A6Q36230572-E7A5899F-52C1-485D-8866-616D8F97B6FCQ36308920-0B5C77BE-8BDB-4EBD-A560-6C8FDE40DF9DQ36354166-2DC56A34-275F-4694-9FA6-810DC7BA77A8Q36492038-940A740A-D6DB-47F8-8ECB-26D3D9E1FA74Q36528900-F490C129-9CF1-4973-BE2D-8394206170D9Q36613817-0FE997AB-2ADE-455D-9E71-FFB568E8C0F1Q36621133-74A36366-1A55-49C7-A25F-169374F4794AQ36621710-42C9271F-83AB-49AA-87BE-F60D4AAB7565
P2860
Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Expression of vascular endothe ...... analysis of serum VEGF levels
@ast
Expression of vascular endothe ...... analysis of serum VEGF levels
@en
type
label
Expression of vascular endothe ...... analysis of serum VEGF levels
@ast
Expression of vascular endothe ...... analysis of serum VEGF levels
@en
prefLabel
Expression of vascular endothe ...... analysis of serum VEGF levels
@ast
Expression of vascular endothe ...... analysis of serum VEGF levels
@en
P2093
P2860
P356
P1476
Expression of vascular endothe ...... analysis of serum VEGF levels
@en
P2093
Sakahara H
Yamamoto S
P2860
P2888
P304
P356
10.1038/BJC.1997.537
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1040576688